Bliss GVS Pharma · NSE: BLISSGVS · BSE: 506197
Q2 FY21 results · Jul–Sep 2020
Bliss GVS Pharma reported revenue from operations of ₹151.54 crore (down 27.9% from Q2 FY20) and net profit of ₹21.61 crore (down 30.0% from Q2 FY20) for Q2 FY21 (Jul–Sep 2020), on a consolidated basis.
| Item | Q2 FY21 | Q2 FY20 | YoY | Q1 FY21 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 151.54 | 210.12 | −27.9% | 129.55 | +17.0% |
| Other income | 2.74 | 12.90 | −78.7% | 7.04 | −61.1% |
| Total income | 154.28 | 223.02 | −30.8% | 136.59 | +13.0% |
| Profit before tax | 30.05 | 33.81 | −11.1% | 20.40 | +47.3% |
| Net profit for the period | 21.61 | 30.86 | −30.0% | 16.65 | +29.8% |
| Attributable to shareholders of the company | 20.51 | 30.98 | −33.8% | 16.19 | +26.6% |
| EPS, basic (₹) | 1.99 | 3.00 | −33.7% | 1.57 | +26.8% |
| Net margin (%) | 14.3 | 14.7 | 12.9 |
| Item | Q2 FY21 | Q2 FY20 | YoY | Q1 FY21 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 118.83 | 104.00 | +14.2% | 114.02 | +4.2% |
| Other income | 3.18 | 12.29 | −74.1% | 6.95 | −54.3% |
| Total income | 122.00 | 116.30 | +4.9% | 120.97 | +0.9% |
| Profit before tax | 26.27 | 30.50 | −13.9% | 20.41 | +28.7% |
| Net profit for the period | 18.79 | 28.44 | −33.9% | 17.10 | +9.9% |
| EPS, basic (₹) | 1.82 | 2.76 | −34.1% | 1.66 | +9.6% |
| Net margin (%) | 15.8 | 27.3 | 15.0 |
Consolidated
- Filed with BSE
- 22 Oct 2020, 18:25 IST
- Board meeting
- 21 Oct 2020
- Period
- 01 Jul 2020 to 30 Sep 2020
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 22 Oct 2020, 18:25 IST
- Board meeting
- 21 Oct 2020
- Period
- 01 Jul 2020 to 30 Sep 2020
- Review status
- Unaudited
- Source
- XBRL filing on BSE